By Chris Wack Syndax Pharmaceuticals shares were up 8% to $18 after the company said it saw positive data from trials of revumenib in combination with.
Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 1.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,492 shares of the company’s stock after purchasing an additional 615 shares […]
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) has been assigned an average rating of “Buy” from the ten brokerages that are covering the stock, Marketbeat reports. Ten analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have updated their coverage on the stock in the last […]
American International Group Inc. raised its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 9.2% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 31,712 shares of the company’s stock after acquiring an additional 2,673 shares during the quarter. American International Group Inc.’s […]